Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Robo.ai is trying to move from a failed smart-EV revenue base into an AI robotics, intelligent hardware and asset platform. The filings show FY2025 revenue of only $0.95 million, a $167.3 million net loss, $4.1 million of cash, $124.6 million of liabilities, n
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
Redwire has fresh space and drone headlines, but the real RDW proof gate is whether record backlog converts into profitable revenue and cash without new dilution pressure.
Enphase reported Q1 2026 results and announced an IQ solid-state transformer program for AI data centers. The proof gate is revenue stabilization, battery shipments, non-GAAP gross margin, and IQ SST progress.
BitMine priced an upsized preferred-stock deal, and the real question is whether ETH treasury growth can beat a new preferred dividend claim that sits ahead of common shareholders.
BMNR said crypto plus cash plus other holdings totaled twelve point three billion dollars as of May 25, 2026. The proof gate is ETH per share, staking yield, cash runway, and NAV transparency.
AST SpaceMobile targeted roughly 45 BlueBird satellites in orbit during 2026 and reported Q1 results. The proof gate is satellite count, revenue ramp, cash balance, and operating expense discipline.
Ashford Hospitality Trust reported better Q1 comparable RevPAR and hotel EBITDA, but the Q1 2026 10-Q includes going-concern doubt, $1.9 billion of near-term non-recourse loan maturities, defaulted loans and suspended preferred dividends. AHT is a high-risk lo
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
AI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
Firefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings
Aeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.